Igc Pharma Inc (IGC)

$0.30 0.00 (-1.30%)
Market Cap 21.52M
Revenue (ttm) 1.35M
Net Income (ttm) -13.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -962.96%
Debt to Equity Ratio 0.02
Volume 101,014
Avg Vol 336,708
Day's Range N/A - N/A
Shares Out 79.69M
Stochastic %K 57%
Beta 1.45
Analysts Sell
Price Target $3.88

Latest News on IGC

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 24, 2025, 9:30 AM EDT - 4 days ago

IGC Pharma Welcomes Strategic Investment from Advisors

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 21, 2025, 9:30 AM EDT - 7 days ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 8, 2025, 9:30 AM EDT - 20 days ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Apr 1, 2025, 9:00 AM EDT - 27 days ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 26, 2025, 9:00 AM EDT - 4 weeks ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

Mar 20, 2025, 9:00 AM EDT - 5 weeks ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

Mar 17, 2025, 9:00 AM EDT - 6 weeks ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Mar 12, 2025, 9:00 AM EDT - 6 weeks ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

Mar 10, 2025, 9:00 AM EDT - 7 weeks ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

Mar 4, 2025, 9:00 AM EST - 7 weeks ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

Feb 20, 2025, 9:00 AM EST - 2 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

IGC Pharma Reports Third Quarter Fiscal 2025 Results

Feb 18, 2025, 8:30 AM EST - 2 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

Feb 11, 2025, 8:30 AM EST - 2 months ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

Jan 28, 2025, 8:30 AM EST - 3 months ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Jan 13, 2025, 8:30 AM EST - 3 months ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Jan 8, 2025, 8:30 AM EST - 3 months ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

Dec 19, 2024, 7:00 PM EST - 4 months ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

Dec 2, 2024, 8:30 AM EST - 5 months ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Nov 25, 2024, 8:30 AM EST - 5 months ago

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

Nov 14, 2024, 8:30 AM EST - 5 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

Nov 6, 2024, 8:30 AM EST - 6 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Oct 17, 2024, 8:30 AM EDT - 6 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

Oct 3, 2024, 9:00 AM EDT - 7 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

Sep 18, 2024, 8:00 AM EDT - 7 months ago

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

Sep 4, 2024, 8:00 AM EDT - 8 months ago

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

Aug 22, 2024, 9:00 AM EDT - 8 months ago

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC Pharma Reports First Quarter Fiscal 2025 Results

Aug 8, 2024, 9:30 PM EDT - 9 months ago

IGC Pharma Reports First Quarter Fiscal 2025 Results

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Jul 18, 2024, 9:00 AM EDT - 10 months ago

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

Jul 9, 2024, 9:10 AM EDT - 10 months ago

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

Jun 25, 2024, 9:00 AM EDT - 10 months ago

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

Jun 10, 2024, 9:00 AM EDT - 11 months ago

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

May 28, 2024, 9:00 AM EDT - 11 months ago

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

IGC Pharma to Attend BIO International Convention 2024

May 21, 2024, 2:00 PM EDT - 1 year ago

IGC Pharma to Attend BIO International Convention 2024

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

Apr 16, 2024, 7:00 AM EDT - 1 year ago

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

IGC Pharma Adds Advisor in Artificial Intelligence

Apr 9, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Adds Advisor in Artificial Intelligence

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

Mar 26, 2024, 3:00 PM EDT - 1 year ago

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation

Mar 20, 2024, 11:00 AM EDT - 1 year ago

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

Mar 20, 2024, 7:00 AM EDT - 1 year ago

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

Mar 12, 2024, 3:00 PM EDT - 1 year ago

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

Feb 23, 2024, 12:01 PM EST - 1 year ago

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Feb 16, 2024, 7:05 PM EST - 1 year ago

IGC Pharma Reports Third Quarter Fiscal 2024 Results

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

Feb 1, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's

Jan 23, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer's

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial

Jan 17, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer's Trial

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's

Dec 19, 2023, 9:20 AM EST - 1 year ago

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer's

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024

Dec 13, 2023, 9:30 AM EST - 1 year ago

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials

Dec 6, 2023, 8:30 AM EST - 1 year ago

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives

Nov 21, 2023, 8:30 AM EST - 1 year ago

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives

IGC Pharma Reports Second Quarter Fiscal 2024 Results

Nov 13, 2023, 8:00 AM EST - 1 year ago

IGC Pharma Reports Second Quarter Fiscal 2024 Results

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy

Oct 19, 2023, 3:30 PM EDT - 1 year ago

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy